SAN DIEGO, CA – FEBRUARY 17, 2026 – Singular Genomics today announced the commercial launch and U.S. availability of its G4X™ Spatial Sequencer, a high-throughput platform enabling simultaneous 500-plex RNA, 18-plex protein, and fluorescent H&E analysis at subcellular resolution from FFPE tissue. The G4X can process 128 samples and 40 cm² per run — nearly 10× the throughput of other commercially available systems — with sample-to-answer in 5 days and per-sample costs in the low hundreds. The launch follows validation across nearly 20,000 FFPE samples, approximately 4 billion spatially resolved single cells, and an Early Access Program at five leading academic medical centers.
“The launch of G4X reflects a clear inflection point for spatial,” said Josh Stahl, CEO of Singular. “With the performance, scale, and affordability we’ve demonstrated, spatial analysis can now move beyond boutique experiments to power large cohorts, translational pipelines, and AI model development. We believe this is the foundation for the next wave of spatial pathology, one defined by clinical relevance, statistical power, and real-world impact.”
Read the full article on singulargenomics.com
Share this page on social